{"id":"NCT02624947","sponsor":"Novavax","briefTitle":"A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization","officialTitle":"A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12","primaryCompletion":"2018-12-28","completion":"2019-07-12","firstPosted":"2015-12-09","resultsPosted":"2025-05-06","lastUpdate":"2025-05-06"},"enrollment":4636,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"RSV F vaccine with adjuvant","otherNames":[]},{"type":"BIOLOGICAL","name":"Formulation buffer","otherNames":[]}],"arms":[{"label":"Treatment Group A","type":"PLACEBO_COMPARATOR"},{"label":"Treatment Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy of maternal immunization during the third trimester of pregnancy with the RSV F vaccine against medically-significant RSV lower respiratory tract infection (LRTI), as defined by hypoxemia or tachypnea at rest, through the first 90, 120, 150, and 180 days of life in infants.","primaryOutcome":{"measure":"Infants: Percentages of Participants With Medically Significant RSV LRTI With Either Hypoxemia (SpO2 <95% at Sea Level or <92% at Altitudes >1800 Meters) or Tachypnea","timeFrame":"Delivery to 180 days after delivery","effectByArm":[{"arm":"Adjuvanted RSV F Vaccine (120 Âµg RSVF Protein Adsorbed to a 0.4 mg Dose of Aluminum)","deltaMin":41,"sd":null},{"arm":"Formulated Buffer (Placebo Control)","deltaMin":35,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":88,"countries":["United States","Argentina","Australia","Bangladesh","Chile","Mexico","New Zealand","Philippines","South Africa","Spain","United Kingdom"]},"refs":{"pmids":["32726529"],"seeAlso":["http://novavax.com"]},"adverseEventsSummary":{"seriousAny":{"events":1356,"n":3045},"commonTop":["Dermatitis diaper","Fever neonatal","Upper respiratory tract infection","Headache","Diarrhoea neonatal"]}}